A Double-blind Phase 2 Study to Assess the Safety and Efficacy of Aloxi (Palonosetron HCl) for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving High-dose Melphalan as Conditioning Chemotherapy for Stem Cell Transplantation

Trial Profile

A Double-blind Phase 2 Study to Assess the Safety and Efficacy of Aloxi (Palonosetron HCl) for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving High-dose Melphalan as Conditioning Chemotherapy for Stem Cell Transplantation

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Palonosetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors MGI Pharma
  • Most Recent Events

    • 15 May 2008 Results will be presented at the Annual Meeting of the American Society of Clinical Oncology 2008.
    • 25 Jul 2007 Status changed from initiated to recruiting.
    • 03 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top